Insider Transactions in Q1 2025 at Veracyte, Inc. (VCYT)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,255
-10.36%
|
$280,670
$34.76 P/Share
|
|
Mar 02
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,070
-8.87%
|
$376,380
$34.76 P/Share
|
|
Mar 02
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,301
-10.55%
|
$146,234
$34.76 P/Share
|
|
Mar 02
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,754
-6.94%
|
$229,636
$34.76 P/Share
|
|
Mar 02
2025
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,324
-5.96%
|
$691,016
$34.76 P/Share
|
|
Mar 02
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
7,650
-9.68%
|
$260,100
$34.76 P/Share
|
|
Feb 27
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
7,000
-8.07%
|
$231,000
$33.84 P/Share
|
|
Feb 27
2025
|
Annie Mc Guire SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
13,466
+13.44%
|
-
|
|
Feb 27
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,911
-8.71%
|
$393,063
$33.84 P/Share
|
|
Feb 27
2025
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,170
+14.49%
|
-
|
|
Feb 27
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,672
-13.87%
|
$517,176
$33.84 P/Share
|
|
Feb 27
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,589
+21.3%
|
-
|
|
Feb 27
2025
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,273
-9.13%
|
$1,131,009
$33.84 P/Share
|
|
Feb 27
2025
|
Marc Stapley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,277
+15.2%
|
-
|
|
Feb 27
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
5,746
-6.77%
|
$189,618
$33.84 P/Share
|
|
Feb 27
2025
|
John Leite Chief Commercial Officer-CLIA |
BUY
Grant, award, or other acquisition
|
Direct |
11,006
+11.49%
|
-
|
|
Feb 03
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
527
-0.46%
|
$22,661
$43.85 P/Share
|
|
Jan 06
2025
|
Robert S Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+23.64%
|
$160,000
$8.04 P/Share
|
|
Jan 02
2025
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
10,000
-19.43%
|
$400,000
$40.31 P/Share
|
|
Jan 02
2025
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+25.98%
|
$50,000
$5.28 P/Share
|